Show simple item record

dc.contributor.authorHirayama, Yuri
dc.contributor.authorDaniels, Natasha Faye
dc.contributor.authorEvans, Shelley
dc.contributor.authorClarke, David
dc.contributor.authorPurvis, Stephenie
dc.contributor.authorOliver, Charlotte
dc.contributor.authorWoodmansey, Stephen
dc.contributor.authorStaniforth, Joy
dc.contributor.authorSoilleux, Elizabeth J
dc.date.accessioned2021-10-30T01:12:37Z
dc.date.available2021-10-30T01:12:37Z
dc.date.issued2021-09-17
dc.identifier.citationDiagnostics (Basel, Switzerland), volume 11, issue 9
dc.identifier.issn2075-4418
dc.identifier.otherPMC8467907
dc.identifier.other34574044
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330085
dc.description.abstractA high prevalence of hepatic pathology (in 17 of 19 cases) was reported in post-mortem (PM) examinations of COVID-19 patients, undertaken between March 2020 and February 2021 by a single autopsy pathologist in two English Coronial jurisdictions. The patients in our cohort demonstrated high levels of recognised COVID-19 risk factors, including hypertension (8/16, 50%), type 2 diabetes mellitus (8/16, 50%) and evidence of arteriopathy 6/16 (38%). Hepatic abnormalities included steatosis (12/19; 63%), moderate to severe venous congestion (5/19; 26%) and cirrhosis (4/19; 21%). A subsequent literature review indicated a significantly increased prevalence of steatosis (49%), venous congestion (34%) and cirrhosis (9.3%) in COVID-19 PM cases, compared with a pre-pandemic PM cohort (33%, 16%, and 2.6%, respectively), likely reflecting an increased mortality risk in SARS-CoV-2 infection for patients with pre-existing liver disease. To corroborate this observation, we retrospectively analysed the admission liver function test (LFT) results of 276 consecutive, anonymised COVID-19 hospital patients in our centre, for whom outcome data were available. Of these patients, 236 (85.5%) had significantly reduced albumin levels at the time of admission to hospital, which was likely indicative of pre-existing chronic liver or renal disease. There was a strong correlation between patient outcome (length of hospital admission or death) and abnormal albumin at the time of hospital admission (<i>p</i> = 0.000012). We discuss potential mechanisms by which our observations of hepatic dysfunction are linked to a risk of COVID-19 mortality, speculating on the importance of recently identified anti-interferon antibodies.
dc.languageeng
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 2075-4418
dc.sourcenlmid: 101658402
dc.subjectPathology
dc.subjectCirrhosis
dc.subjectLiver function tests
dc.subjectAutopsy
dc.subjectSteatosis
dc.subjectPost-mortem
dc.subjectHepatic Pathology
dc.subjectCovid-19
dc.subjectSars-cov-2
dc.subjectInterferon Dysregulation
dc.titleHigh Prevalence of Pre-Existing Liver Abnormalities Identified Via Autopsies in COVID-19: Identification of a New Silent Risk Factor?
dc.typeArticle
dc.date.updated2021-10-30T01:12:36Z
dc.identifier.doi10.17863/CAM.77529
rioxxterms.versionofrecord10.3390/diagnostics11091703
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidDaniels, Natasha Faye [0000-0003-0384-0542]
dc.contributor.orcidEvans, Shelley [0000-0003-3242-6017]
dc.contributor.orcidStaniforth, Joy [0000-0003-2817-0098]
dc.contributor.orcidSoilleux, Elizabeth J [0000-0002-4032-7249]


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International